Market capitalization | $198.11b |
Enterprise Value | $205.88b |
P/E (TTM) P/E ratio | 35.94 |
EV/FCF (TTM) EV/FCF | 36.41 |
EV/Sales (TTM) EV/Sales | 5.06 |
P/S ratio (TTM) P/S ratio | 4.86 |
P/B ratio (TTM) P/B ratio | 5.04 |
Dividend yield | 1.83% |
Last dividend (FY23) | $2.08 |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
27 Analysts have issued a Abbott Laboratories forecast:
27 Analysts have issued a Abbott Laboratories forecast:
Jun '24 |
+/-
%
|
||
Revenue | 40,725 40,725 |
1%
1%
|
|
Gross Profit | 20,619 20,619 |
3%
3%
|
|
EBITDA | 9,860 9,860 |
6%
6%
|
EBIT (Operating Income) EBIT | 6,613 6,613 |
9%
9%
|
Net Profit | 5,536 5,536 |
8%
8%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
Head office | United States |
CEO | Robert Ford |
Employees | 114,000 |
Founded | 1888 |
Website | www.abbott.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.